Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Nektar Therapeutics (NKTR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$36.15-6.06%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for NKTR yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage capital through stock offerings | The company focuses on its REZOLVE-AA study and managing capital through stock offerings. | Intact | No equity offerings or capital raises for 12 months | Equity Distribution Agreement active (May 2026) NKTR entered a $150M Equity Distribution Agreement with Guggenheim and Wainwright on May 8, 2026, confirming active capital access. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-development company, not an established earnings compounder. Its thesis is in a watch state: trial plans and funding are progressing, while confidence has eased from high to medium and recent performance remains weak.
NKTR trades at a sizable premium versus peers, supported by the expectation of durable value from its clinical program. The expectations gap is negative, which suggests the premium may assume more progress than current fundamentals support; confidence in the valuation model is low.
Near term, results may remain uneven, given the company is loss-making and recent financial performance sits well below its industry cohort. Management has started planned Phase 3 work and strengthened cash resources, which support development into 2028, but trial execution and clinical evidence remain central risks.
Over the multi-year view, the thesis depends on rezpegaldesleukin advancing through planned trials and showing convincing efficacy and safety, especially in alopecia areata. Healthcare sector momentum may help or fade depending on results and guidance from bellwethers, while weaker employment data could add pressure to cyclical names.
NKTR has a funded clinical-development plan and encouraging but mixed evidence, alongside a premium valuation, weak recent performance, and elevated risk. The 1-3 year view hinges on trial progress and whether clinical results justify the expectations already reflected in that premium. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company focuses on its REZOLVE-AA study and managing capital through stock offerings. |
| Intact |
| New negative clinical trial results reported |
Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
EPS loss narrows toward zero | A primary condition in Nektar Therapeutics's published investment case. The stated target is EPS loss less than -0.5 next quarter. | Broken | EPS loss worsens beyond -0.5 next quarter | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue decline moderates and stabilizes | A primary condition in Nektar Therapeutics's published investment case. The stated target is revenue decline better than -10% YoY. | Broken | revenue decline worsens beyond -10% YoY | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-11.87 → $-10.50 · observed estimates
$0.04B → $0.05B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-11.87 | $36,987,460 | 5 / 11 |
| 2026-07-25 | $-10.93 | $36,906,208 | 7 / 9 |
| 2026-07-26 | $-10.77 | $36,987,462 | 7 / 9 |
| 2026-07-27 | $-11.87 | $36,987,460 | 5 / 11 |
| 2026-07-28 | $-11.87 | $36,987,460 | 5 / 11 |
| 2026-07-29 | $-11.87 | $36,987,460 | 5 / 11 |
| 2026-07-30 | $-11.87 | $36,987,460 | 5 / 11 |
| 2026-07-31 | $-11.87 | $36,987,460 | 5 / 11 |
| 2026-08-01 | $-10.77 | $36,987,462 | 8 / 9 |
| 2026-08-02 | $-10.77 | $36,987,462 | 8 / 9 |
| 2026-08-03 | $-10.77 | $36,987,462 | 8 / 9 |
| 2026-08-04 | $-10.77 | $36,987,462 | 8 / 9 |
| 2026-08-05 | $-10.77 | $36,987,462 | 8 / 9 |
| 2026-08-06 | $-10.77 | $36,987,462 | 8 / 9 |
| 2026-08-07 | $-10.77 | $36,987,462 | 8 / 9 |
| 2026-08-08 | $-11.87 | $36,987,460 | 5 / 11 |
| 2026-08-09 | $-11.87 | $36,987,460 | 5 / 11 |
| 2026-08-10 | $-10.77 | $36,987,462 | 8 / 9 |
| 2026-08-12 | $-10.77 | $36,987,462 | 8 / 9 |
| 2026-08-13 | $-10.77 | $36,987,462 | 8 / 9 |
| 2026-08-14 | $-10.77 | $36,987,462 | 8 / 9 |
| 2026-08-15 | $-10.77 | $36,987,462 | 8 / 9 |
| 2026-08-16 | $-10.77 | $36,987,462 | 8 / 9 |
| 2026-08-17 | $-10.77 | $36,987,462 | 8 / 9 |
| 2026-08-18 | $-10.77 | $36,987,462 | 8 / 9 |
| 2026-08-19 | $-10.77 | $36,987,462 | 8 / 9 |
| 2026-08-20 | $-10.45 | $58,544,903 | 7 / 9 |
| 2026-08-21 | $-10.45 | $58,541,266 | 7 / 9 |
| 2026-08-22 | $-10.45 | $58,541,266 | 7 / 9 |
| 2026-08-23 | $-10.54 | $56,996,161 | 8 / 10 |
| 2026-08-24 | $-10.54 | $56,996,161 | 8 / 10 |
| 2026-08-25 | $-10.54 | $56,996,161 | 8 / 10 |
| 2026-08-26 | $-10.54 | $56,996,161 | 8 / 10 |
| 2026-08-27 | $-10.54 | $56,996,161 | 8 / 10 |
| 2026-08-28 | $-10.54 | $56,996,161 | 8 / 10 |
| 2026-08-29 | $-10.54 | $56,996,161 | 8 / 10 |
| 2026-08-30 | $-10.54 | $56,996,161 | 8 / 10 |
| 2026-08-31 | $-10.54 | $56,996,161 | 8 / 10 |
| 2026-09-01 | $-10.54 | $56,996,161 | 8 / 10 |
| 2026-09-02 | $-10.54 | $56,996,161 | 8 / 10 |
| 2026-09-03 | $-10.54 | $56,996,161 | 8 / 10 |
| 2026-09-04 | $-10.54 | $56,996,161 | 8 / 10 |
| 2026-09-05 | $-10.54 | $56,996,161 | 8 / 10 |
| 2026-09-06 | $-10.54 | $56,996,161 | 8 / 10 |
| 2026-09-07 | $-10.54 | $56,996,161 | 8 / 10 |
| 2026-09-08 | $-10.54 | $56,996,161 | 8 / 10 |
| 2026-09-09 | $-10.54 | $56,996,161 | 8 / 10 |
| 2026-09-10 | $-10.53 | $56,996,161 | 8 / 10 |
| 2026-09-11 | $-10.54 | $56,996,161 | 8 / 10 |
| 2026-09-12 | $-10.53 | $56,996,161 | 8 / 10 |
| 2026-09-13 | $-10.53 | $56,996,161 | 8 / 10 |
| 2026-09-14 | $-10.53 | $56,996,161 | 8 / 10 |
| 2026-09-15 | $-10.53 | $56,996,161 | 8 / 10 |
| 2026-09-16 | $-10.53 | $56,996,161 | 8 / 10 |
| 2026-09-17 | $-10.54 | $56,996,161 | 8 / 10 |
| 2026-09-18 | $-10.54 | $56,996,161 | 8 / 10 |
| 2026-09-19 | $-10.53 | $56,996,161 | 8 / 10 |
| 2026-09-20 | $-10.53 | $56,996,161 | 8 / 10 |
| 2026-09-21 | $-10.53 | $56,996,161 | 8 / 10 |
| 2026-09-22 | $-10.53 | $56,996,161 | 8 / 10 |
| 2026-09-23 | $-10.53 | $56,996,161 | 8 / 10 |
| 2026-09-24 | $-10.53 | $56,996,161 | 8 / 10 |
| 2026-09-25 | $-10.25 | $56,996,161 | 8 / 10 |
| 2026-09-26 | $-10.25 | $56,993,103 | 8 / 10 |
| 2026-09-27 | $-10.25 | $56,993,103 | 8 / 10 |
| 2026-09-28 | $-10.25 | $56,993,103 | 8 / 10 |
| 2026-09-29 | $-10.25 | $56,993,103 | 8 / 10 |
| 2026-09-30 | $-10.25 | $56,993,103 | 8 / 10 |
| 2026-10-01 | $-10.25 | $56,996,436 | 11 / 10 |
| 2026-10-02 | $-10.25 | $56,996,436 | 11 / 10 |
| 2026-10-03 | $-10.25 | $56,996,436 | 11 / 10 |
| 2026-10-04 | $-10.25 | $56,996,436 | 11 / 10 |
| 2026-10-05 | $-10.25 | $56,996,436 | 11 / 10 |
| 2026-10-06 | $-10.25 | $56,996,436 | 11 / 10 |
| 2026-10-07 | $-10.25 | $56,996,436 | 11 / 10 |
| 2026-10-08 | $-10.25 | $56,996,436 | 11 / 10 |
| 2026-10-09 | $-10.25 | $56,996,436 | 11 / 10 |
| 2026-10-10 | $-10.37 | $55,991,710 | 11 / 11 |
| 2026-10-11 | $-10.37 | $55,991,710 | 11 / 11 |
| 2026-10-12 | $-10.37 | $55,991,710 | 11 / 11 |
| 2026-10-13 | $-10.50 | $53,419,482 | 12 / 11 |
| 2026-10-14 | $-10.50 | $53,419,482 | 13 / 13 |
| 2026-10-15 | $-10.50 | $53,419,482 | 13 / 13 |
| 2026-10-16 | $-10.50 | $53,419,482 | 13 / 13 |
| 2026-10-17 | $-10.50 | $53,419,482 | 13 / 13 |
| 2026-10-18 | $-10.50 | $53,419,482 | 13 / 13 |
| 2026-10-19 | $-10.50 | $53,419,482 | 13 / 13 |
| 2026-10-20 | $-10.50 | $53,419,482 | 13 / 13 |
| 2026-10-21 | $-10.50 | $53,419,482 | 13 / 13 |
| 2026-10-22 | $-10.50 | $53,419,482 | 13 / 13 |
| 2026-10-23 | $-10.50 | $53,419,482 | 13 / 13 |
| 2026-10-24 | $-10.50 | $53,419,482 | 13 / 13 |
| 2026-10-25 | $-10.50 | $53,419,482 | 13 / 13 |
| 2026-10-26 | $-10.50 | $53,419,482 | 13 / 13 |
| 2026-10-27 | $-10.50 | $53,419,482 | 13 / 13 |
| 2026-10-28 | $-10.50 | $53,419,482 | 13 / 13 |
| 2026-10-29 | $-10.50 | $53,419,482 | 13 / 13 |
| 2026-10-30 | $-10.50 | $53,419,482 | 13 / 13 |
| 2026-10-31 | $-10.50 | $53,419,482 | 13 / 13 |
| 2026-11-01 | $-10.50 | $53,419,482 | 13 / 13 |
| 2026-11-02 | $-10.50 | $53,419,482 | 13 / 13 |
| 2026-11-03 | $-10.50 | $53,419,482 | 13 / 13 |
| 2026-11-04 | $-10.50 | $53,419,482 | 13 / 13 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 11 Buy / Strong Buy · 4 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
0 raises · 0 cuts · 0 unchanged · 2 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.